Cancer Research Targets  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosanò, L.
Right arrow Articles by Bagnato, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosanò, L.
Right arrow Articles by Bagnato, A.
[Cancer Research 65, 11649-11657, December 15, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells

Laura Rosanò1, Francesca Spinella1, Valeriana Di Castro1, Maria Rita Nicotra2, Shoukat Dedhar3, Antonio Garcia de Herreros4, Pier Giorgio Natali1 and Anna Bagnato1

1 Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute; 2 Molecular Biology and Pathology Institute, National Research Council, Rome, Italy; 3 British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada; and 4 Unitat de Biologia Cellular i Molecular, Institut Municipal d'Investigació Mèdica, Universitat Pompeu Fabra, Barcelona, Spain

Requests for reprints: Anna Bagnato, Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi D'Oro 156, 00158 Rome, Italy. Phone: 39-06-5266-2565; Fax: 39-06-5266-2600; E-mail: bagnato{at}ifo.it.

Despite considerable efforts to improve early detection and advances in chemotherapy, metastatic relapses remain a major challenge in the management of ovarian cancer. The endothelin A receptor (ETAR)/endothelin-1 (ET-1) axis has been shown to have a significant role in ovarian carcinoma by promoting tumorigenesis. Here we show that the ET-1/ETAR autocrine pathway drives epithelial-to-mesenchymal transition (EMT) in ovarian tumor cells by inducing a fibroblastoid and invasive phenotype, down-regulation of E-cadherin, increased levels of ß-catenin, Snail, and other mesenchymal markers, and suppression of E-cadherin promoter activity. Activation of ETAR by ET-1 triggers an integrin-linked kinase (ILK)–mediated signaling pathway leading to glycogen synthase kinase-3ß (GSK-3ß) inhibition, Snail and ß-catenin stabilization, and regulation of transcriptional programs that control EMT. Transfection of dominant negative ILK or exposure to an ILK inhibitor suppresses the ET-1-induced phosphorylation of GSK-3ß as well as Snail and ß-catenin protein stability, activity, and invasiveness, indicating that ET-1/ETAR–induced EMT-promoting effects depend on ILK. ETAR blockade by specific antagonists or reduction by ETAR RNA interference reverses EMT and cell invasion by inhibiting autocrine signaling pathways. In ovarian carcinoma xenografts, ABT-627, a specific ETAR antagonist, suppresses EMT determinants and tumor growth. In human ovarian cancers, ETAR expression is associated with E-cadherin down-regulation, N-cadherin expression, and tumor grade. Collectively, these findings provide evidence of a critical role for the ET-1/ETAR axis during distinct steps of ovarian carcinoma progression and identify novel targets of therapeutic intervention. (Cancer Res 2005; 65(24): 11649-57)




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Ghoul, M. Serova, L. Astorgues-Xerri, I. Bieche, G. Bousquet, M. Varna, M. Vidaud, E. Phillips, S. Weill, K. A. Benhadji, et al.
Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells
Cancer Res., May 15, 2009; 69(10): 4260 - 4269.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Rosano, R. Cianfrocca, S. Masi, F. Spinella, V. Di Castro, A. Biroccio, E. Salvati, M. R. Nicotra, P. G. Natali, and A. Bagnato
{beta}-Arrestin links endothelin A receptor to {beta}-catenin signaling to induce ovarian cancer cell invasion and metastasis
PNAS, February 24, 2009; 106(8): 2806 - 2811.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. V. Shah, A. Muralidharan, M. Gokulgandhi, K. Soan, and S. Thomas
Cadherin Switching and Activation of {beta}-Catenin Signaling Underlie Proinvasive Actions of Calcitonin-Calcitonin Receptor Axis in Prostate Cancer
J. Biol. Chem., January 9, 2009; 284(2): 1018 - 1030.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
P. C. McDonald, A. B. Fielding, and S. Dedhar
Integrin-linked kinase - essential roles in physiology and cancer biology
J. Cell Sci., October 1, 2008; 121(19): 3121 - 3132.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. I. Ager, J. Neo, and C. Christophi
The renin-angiotensin system and malignancy
Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. L. Pon, H. Y. Zhou, A. N.Y. Cheung, H. Y.S. Ngan, and A. S.T. Wong
p70 S6 Kinase Promotes Epithelial to Mesenchymal Transition through Snail Induction in Ovarian Cancer Cells
Cancer Res., August 15, 2008; 68(16): 6524 - 6532.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T.-V. Do, L. A. Kubba, M. Antenos, A. W. Rademaker, C. D. Sturgis, and T. K. Woodruff
The Role of Activin A and Akt/GSK Signaling in Ovarian Tumor Biology
Endocrinology, August 1, 2008; 149(8): 3809 - 3816.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Iribarne, L. Ogawa, V. Torbidoni, C. M. Dodds, R. A. Dodds, and A. M. Suburo
Blockade of Endothelinergic Receptors Prevents Development of Proliferative Vitreoretinopathy in Mice
Am. J. Pathol., April 1, 2008; 172(4): 1030 - 1042.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Shell, S.-M. Park, A. R. Radjabi, R. Schickel, E. O. Kistner, D. A. Jewell, C. Feig, E. Lengyel, and M. E. Peter
Let-7 expression defines two differentiation stages of cancer
PNAS, July 3, 2007; 104(27): 11400 - 11405.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Rosano, V. Di Castro, F. Spinella, G. Tortora, M. R. Nicotra, P. G. Natali, and A. Bagnato
Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity
Cancer Res., July 1, 2007; 67(13): 6351 - 6359.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
R. Jain, P. W. Shaul, Z. Borok, and B. C. Willis
Endothelin-1 Induces Alveolar Epithelial-Mesenchymal Transition through Endothelin Type A Receptor-Mediated Production of TGF-beta1
Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 38 - 47.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Rosano, V. Di Castro, F. Spinella, M. R. Nicotra, P. G. Natali, and A. Bagnato
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo
Mol. Cancer Ther., July 1, 2007; 6(7): 2003 - 2011.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
M J Grimshaw
Endothelins and hypoxia-inducible factor in cancer
Endocr. Relat. Cancer, June 1, 2007; 14(2): 233 - 244.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Banerjee, M. Hussain, Z. Wang, A. Saliganan, M. Che, D. Bonfil, M. Cher, and F. H. Sarkar
In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer
Cancer Res., April 15, 2007; 67(8): 3818 - 3826.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
G. A. Clines, K. S. Mohammad, Y. Bao, O. W. Stephens, L. J. Suva, J. D. Shaughnessy Jr., J. W. Fox, J. M. Chirgwin, and T. A. Guise
Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation
Mol. Endocrinol., February 1, 2007; 21(2): 486 - 498.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Davidson, Z. Zhang, L. Kleinberg, M. Li, V. A. Florenes, T.-L. Wang, and I.-M. Shih
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
Clin. Cancer Res., October 15, 2006; 12(20): 5944 - 5950.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. Spinella, L. Rosano, V. Di Castro, S. Decandia, A. Albini, M. R. Nicotra, P. G. Natali, and A. Bagnato
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
Mol. Cancer Ther., June 1, 2006; 5(6): 1483 - 1492.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Rosano, F. Spinella, V. Di Castro, S. Dedhar, M. R. Nicotra, P. G. Natali, and A. Bagnato
Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.
Mol. Cancer Ther., April 1, 2006; 5(4): 833 - 842.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.